PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 1, 1983Clinical Pharmacology & Therapeutics210 citations

Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite

View Full Paper
CSCheck Y. SumAYAvraham YacobiRKRonald Kartzinel

Key Points

Key points are not available for this paper at this time.

Abstract

Esmolol is an ultra-short-acting beta blocker. Its kinetics was studied in eight healthy subjects after continuous intravenous infusion of 400 micrograms/kg/min over 2 hr. The concentrations of esmolol and its major metabolite, 3-4-(2-hydroxy-3-[isopropylaminopropoxy)phenyl]propionic acid, in blood and urine were determined by gas chromatographic-mass spectrometric assay and HPLC. The distribution and elimination t1/2s of esmolol averaged 2.03 and 9.19 min. The apparent volume of distribution of esmolol averaged 3.43 l/kg and was four times the volume of the central compartment. The total clearance of esmolol averaged 285 ml/min/kg, indicating that nonhepatic routes play a predominant role in its clearance. The t1/2s of formation and elimination of the metabolite averaged 2.82 min and 3.72 hr. The ratio of the metabolite formation and elimination rate constants of the parent drug (kf/k10) averaged 0.829, suggesting that 82.9% of esmolol was converted to the metabolite (which is consistent with the urinary recovery of 71% of the dose as unconjugated metabolite). The volume of distribution and total clearance of the metabolite averaged 0.411 l/kg and 1.28 ml/min/kg. Esmolol was followed by a significant reduction of isoproterenol-induced increase in heart rate and systolic blood pressure at doses of 50, 150, and 400 micrograms/kg/min.(ABSTRACT TRUNCATED AT 250 WORDS)

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sum et al. (1983) studied this question.

synapsesocial.com/papers/6a632feebc34223c9a2881ffhttps://doi.org/10.1038/clpt.1983.193
Ask AI
Helpful
Bookmark
Share
View Full Paper